Abstract: Thyroid dysfunction produces marked cardiovascular responses. Hypothyroidism and hyperthyroidism cause important changes in the circulating renin-angiotensin system (RAS). Modifications in cardiac RAS have also been involved in cardiovascular alterations. Studies have revealed that thyroid hormones activate some components of cardiac RAS. Angiotensin (Ang) peptides are regulated by the activity of several aminopeptidases (AP) called angiotensinases. Previous results in our laboratory have demonstrated that thyroid dysfunction altered angiotensinase activities in hypothalamus, pituitary, and kidney. In the present study, we investigated the relationship between thyroid status and local angiotensinase activities in the atrium of hypothyroid, euthyroid, and hyperthyroid adult male rats. We have determined fluorometrically soluble and membrane-bound alanyl, glutamyl, and aspartyl aminopeptidase activities using naphthylamide derivatives as substrates. These activities have been, respectively, involved in the metabolism of Ang III to Ang IV, Ang II to Ang III, and Ang I to des-Asp Ang I. Hyperthyroidism was induced with subcutaneous injections of tetraiodothyronine (300 mg/kg/day), and the hypothyroid rats were obtained with 0.03% methimazole via the drinking water. Compared with that in euthyroid rats, a highly significant increase (by 50%) of soluble aspartyl aminopeptidase activity (P , 0.001) was observed in the atrium of hyperthyroid and hypothyroid animals. In membrane fractions, T 4 treatment produced an increase in alanyl aminopeptidase (37%; P , 0.05) and aspartyl aminopeptidase activities (30%; P , 0.01). These results suggest higher formation of des-Asp Ang I in both hypothyroid and hyperthyroid rats but also suggest higher metabolism of Ang III to Ang IV in hyperthyroid animals, which is in agreement with the described alterations of cardiac RAS after thyroid dysfunction.
INTRODUCTION
Increased or reduced action of thyroid hormone on certain molecular pathways in the heart and vasculature causes relevant cardiovascular derangement. It is well established that hyperthyroidism induces a hyperdynamic cardiovascular state, whereas hypothyroidism is characterized by the opposite changes. 1 Although still somewhat controversial, 2 the existence of a complete cardiac intracellular renin-angiotensin system (RAS) was proposed. The components of the RAS could therefore acts as an intracrine hormonal system in which none of them would have to be secreted into the extracellular space to produce their biological action. 3, 4 In the normal human heart, there is a decreasing angiotensin (Ang) receptor density from the right atrium to the left ventricle. In right atrial membranes prepared from pathologic hearts, the percentage of AT 1 receptor decreases with the severity of cardiac dysfunction, whereas that of AT 2 receptor increases. Treatment of hypertrophic rats with AT 1 receptor antagonists inhibits cardiac hypertrophy and reverses the increase receptor density, indicating involvement of this Ang II receptor subtype. The role of the AT 2 receptor is still largely unknown, but it may be involved in cell growth and proliferation. [5] [6] [7] In general terms, whereas hyperthyroidism activated the activity of the plasma RAS, hypothyroidism reduced it. Thyroid dysfunction causes significant changes in angiotensinogen, plasma renin activity, and in Ang receptor density, especially of the AT 2 subtype. 8 Ang II is usually considered the main effector peptide of the RAS. However, other Ang I and Ang II metabolic derivatives, such as des-Asp Ang I, Ang III, or Ang IV, should also be considered. Ang I is converted to des-Asp Ang I by means of aspartyl aminopeptidase [AspAP; Election Commission (EC) 3. 10 Ang III is a less potent vasoconstrictor than Ang II; it stimulates aldosterone secretion and is a neuronal stimulus. Its affinity for the AT 1 and AT 2 receptors is similar. 9, 11 Recently, the AT 4 receptor, with high affinity for Ang IV, was identified as the insulin-regulated aminopeptidase and also appears to play a role in regulating local blood flows. 12 Thyroid dysfunction modifies angiotensinase activities in hypothalamus and pituitary 13 and kidney. 14 Hyperthyroidism in dog up-regulated the Ang receptor expression in the left ventricle, whereas it down-regulated it in the right atrium. 15 Despite their increasing physiopathologic meaning, there are no studies on other active Ang peptides than Ang II in the atrium during thyroid disorders. Atrial natriuretic factor is sometimes considered a physiologic antagonist of the renin-Ang-aldosterone system because it opposes many of the direct biological actions of Ang II and aldosterone, especially in regulating fluid volume and blood pressure homeostasis. More than 95% of the circulating atrial natriuretic factor is derived from cardiac atria, although some ventricular synthesis occurs as well, especially with ventricular hypertrophy. 16 Because of the clinically significant association between atrial natriuretic factor and Ang II and the importance of the atrium in the endocrine function of the heart, it was indicated to investigate in more detail the relationship between local atrial angiotensinase activities and the thyroid status. Therefore, AlaAP, GluAP, and AspAP, involved respectively in the metabolism of Ang III, Ang II, and Ang I, were analyzed in the atrium of hypothyroid, euthyroid, and hyperthyroid adult male rats. Although activation of cell membrane-bound receptors is crucial in the physiologic actions of the RAS, recent evidences suggest that angiotensinases' intracellular location and subsequent degradation of Ang I and Ang II might also be important for some physiologic response.
14 Therefore, in this study, AP activities were analyzed in the soluble (SOL) and membranebound (MEMB) fractions.
METHODS
Twenty male Sprague-Dawley rats weighing 180-200 g were used in this study. The animals were randomly divided into 3 groups: euthyroid (n = 7), hypothyroid (n = 7), and hyperthyroid (n = 6). The animals were kept in a temperaturecontrolled room (24 6 1°C) with a 12-h/12-h light/dark schedule and housed in standard laboratory cages. Laboratory food and water were provided ad libitum. Hyperthyroidism was induced with daily subcutaneous injections of tetraiodothyronine (300 mg/kg/day) for 6 weeks. Hypothyroid rats were obtained with 0.03% methimazole in the drinking water for 6 weeks. These treatments, compared with that for euthyroid animals, have demonstrated significant increases and decreases of serum T 4 ; serum T 3 ; mean arterial pressure; heart rate; pulse pressure; and final thyroid, renal, ventricular, and body weights. 17 Then, the animals were perfused with saline transcardially under equithesin anesthesia (2 mL/kg body weight). Their right atria were quickly removed (less than 60 seconds) and cooled in dry ice. From these samples, we obtained the SOL and MEMB fractions as previously described.
14 Aminopeptidase activities and proteins were measured in triplicate, respectively, in a fluorometric and colorimetric assay as previously described. 14 The method is based on the hydrolytic capacity of aminopeptidases on the substrates amino acid-b-naphthylamides (arylamides) 
RESULTS
Results are shown in Figure 1 . The results demonstrated a similar qualitative profile for SOL and MEMB fractions in the atrium of the different groups studied. In the SOL fraction, the highest levels of activity were observed for AlaAP activity, with 3 orders of magnitude higher than GluAP and AspAP activities. Similarly, in the MEMB fraction, AlaAP exhibited the highest levels of activity, with 2 orders of magnitude higher than GluAP and AspAP. In both SOL and MEMB fractions, GluAP showed the lowest levels of activity. Compared with that in euthyroid rats, a highly significant increase (50% higher) of SOL AspAP activity (P , 0.001) was observed in the atrium of hyperthyroid and hypothyroid animals, but no differences between groups were observed for GluAP and AlaAP. In MEMB fractions, hyperthyroidism induced by T 4 treatment led to an increase in AlaAP (37%; P , 0.05) and AspAP activities (30%; P , 0.01), without changes for GluAP.
DISCUSSION
Compared to lower availability of des-Asp Ang I in euthyroid animals, hypothyroid and hyperthyroid animals exhibited a significant increase of AspAP activity, without changes in GluAP activity. AspAP metabolizes Ang I to desAsp Ang I, and GluAP metabolizes Ang II to Ang III. Therefore, the present results demonstrated higher levels of des-Asp Ang I in both thyroid disorders. This unexpected observation may suggest a dual effect of thyroid hormones on AspAP activity in the atrium. High levels, like low levels, of thyroid hormones in hyper-and hypothyroid animals increased the formation of this Ang peptide. Instead of Ang II formation, an alternative pathway in the metabolism of Ang I develops, leading to the production of des-Asp Ang I by means of AspAP activity. Des-Asp Ang I is not just an intermediate peptide in the degradation of Ang I; it seems to counteract the actions of Ang II, eg, attenuation of the central pressor action of Ang II and the Ang II-induced hypertrophy and hyperplasia in cardiomyocytes and vascular smooth cells, respectively. 10 DesAsp Ang I also improves pathologies in which Ang II has been implicated, eg, attenuation of cardiac hypertrophy in rats with abdominal aortic coarctation, attenuation of neointimal formation in balloon-catheter-injured rat carotid artery, and age-related vascular hypertrophy. Organ bath experiments indicate that des-Asp Ang I acts via the AT 1 receptor and its actions are indomethacin-sensitive, which is also seen in its in vivo anticardiac hypertrophic actions. 18 In addition, our results showing no changes in the enzyme (GluAP) that metabolizes Ang II are in agreement with the previous results that reported no changes in atrial Ang II receptor densities in hyperthyroidism. 15 On the other hand, hyperthyroid rats also exhibited a significant increase in MEMB AlaAP activity, which suggests higher formation of Ang IV in this thyroid disorder. The Ang AT 4 receptor was originally defined as the specific, highaffinity binding site for the hexapeptide Ang IV. This receptor has a broad distribution and is found in a range of tissues, including the adrenal gland, kidney, lung, and heart. In the kidney, Ang IV increases renal cortical blood flow and decreases Na(+) transport in isolated renal proximal tubules.
The AT 4 receptor has recently been identified as the transmembrane enzyme, insulin-regulated membrane aminopeptidase, which is a type II integral membrane-spanning protein belonging to the M1 family of aminopeptidases and is predominantly found in GLUT4 vesicles in insulin-responsive cells. 12 There is 10-fold more AT 4 receptor than AT 1 receptor in rabbit myocardium. AT 4 receptor agonism has mixed effects on left ventricular systolic function, depressing pressuregeneration and ejection capabilities but enhancing the sensitivity of pressure development to volume change. It also speeds relaxation. The effect of Ang IV on systolic function is generally opposite to the effect of Ang II. 19 Thyroid hormones exert important effects on the cardiovascular system, including effects on cardiac systolic and diastolic function, peripheral vascular resistance, and arrhythmogenesis. Hyperthyroidism and hypothyroidism often cause opposing effects on cardiovascular physiology. 20 The majority of cardiac adaptations to changes in thyroid function are physiologic; however, certain patients do demonstrate clinical evidence of cardiac disease. Atrial arrhythmias, limitations in exercise tolerance, and congestive heart failure are reported to occur as a result of hyperthyroidism. Thyroid hormone also plays an important role in the regulation of blood pressure. Diastolic hypertension is a common symptom observed in hypothyroidism.
Hyperthyroidism manifests a hyperdynamic circulation, with increased cardiac output, increased heart rate, and decreased peripheral resistance. 21 Hyperthyroidism is accompanied by hyperactivity of the RAS. Hemodynamic alteration linked to change in RAS activation may also explain part of the results, but this was not investigated. Thus, plasma renin activity and aldosterone are directly related to plasma levels of thyroid hormones. 22 Hyperthyroidism markedly increased AT 2 -subtype density in ventricle and decreased AT 1 -subtype density. 8 The RAS plays an important role in the increased blood pressure (BP) and renal alterations of hypertensive hyperthyroid rats. 22 It has been suggested that the activated cardiac RAS of hyperthyroidism plays a role in the development of the cardiac hypertrophy of this disease. 23 RAS blockade with either ACE inhibitor or AT1 receptor antagonist contributed to the regression of cardiac hypertrophy in the hyperthyroid state. 24, 25 In conclusion, we report here for the first time evidence for an altered Ang metabolism in the atrium of hypothyroid and hyperthyroid rats. Our results demonstrated increased levels of SOL AspAP activity in the atrium of both hypothyroid and hyperthyroid rats and increased levels of MEMB AlaAP and AspAP activities in hyperthyroid rats, which may imply an increased metabolism of Ang II to des-Asp Ang I and of Ang III to Ang IV. In consequence, hyperthyroid rats may have less available ANG II and ANG III, together with higher levels of des-Asp Ang I and Ang IV, which could be related to the alterations in the contractile and electrophysiologic function of the heart in these thyroid disorders. However, with the present data, we cannot conclude whether changes in AP activities are due to a primary effect of the hormone itself or to secondary effects of the hormone induced by the hemodynamic alterations in hypo-and hyperthyroidism. Therefore, because hypo-and hyperthyroidism produce similar increase in des-Asp Ang I, it could also be proposed that atrial AspAP 
